相似文献
1
Thrombotic Microangiopathy and the Kidney.
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):300-317. doi: 10.2215/CJN.00620117. Epub 2017 Oct 17.
2
Recent advances in the management of atypical hemolytic uremic syndrome.
Clin Adv Hematol Oncol. 2012 Aug;10(8):537-9.
3
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and treatment.
Cleve Clin J Med. 2001 Oct;68(10):857-8, 860, 863-4 passim. doi: 10.3949/ccjm.68.10.857.
4
Atypical hemolytic uremic syndrome: a case report.
J Med Case Rep. 2020 Jan 13;14(1):11. doi: 10.1186/s13256-019-2334-y.
5
Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes.
Crit Care Med. 2018 Sep;46(9):e904-e911. doi: 10.1097/CCM.0000000000003292.
6
Haemolytic uremic syndrome: diagnosis and management.
F1000Res. 2019 Sep 25;8. doi: 10.12688/f1000research.19957.1. eCollection 2019.
7
Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.
Eur J Intern Med. 2013 Sep;24(6):486-91. doi: 10.1016/j.ejim.2013.05.007. Epub 2013 Jun 2.
8
[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics].
Rev Med Interne. 2017 Dec;38(12):817-824. doi: 10.1016/j.revmed.2017.06.004. Epub 2017 Jul 12.
9
Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Nephrology (Carlton). 2018 Jun;23(6):507-517. doi: 10.1111/nep.13234.
10
Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review.
BMC Nephrol. 2025 Mar 27;26(1):158. doi: 10.1186/s12882-025-04080-9.
引用本文的文献
1
Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective.
Nephrology (Carlton). 2025 Sep;30(9):e70116. doi: 10.1111/nep.70116.
2
Growth differentiation factor 11 attenuates sepsis-associated acute kidney injury by reducing inflammation and coagulation via PGC-1α/Nrf2 activation.
Cell Mol Biol Lett. 2025 Aug 28;30(1):102. doi: 10.1186/s11658-025-00762-2.
3
Thrombotic Microangiopathy After Lung Transplantation: A Retrospective Observational Multicenter Cohort Study.
JHLT Open. 2025 Jul 8;9:100335. doi: 10.1016/j.jhlto.2025.100335. eCollection 2025 Aug.
4
Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China.
Front Endocrinol (Lausanne). 2025 Jun 27;16:1568082. doi: 10.3389/fendo.2025.1568082. eCollection 2025.
5
Diagnostic Value of Biological Parameters in Biopsy-Confirmed Thrombotic Microangiopathy-MATRIX Consortium Group.
Kidney Int Rep. 2025 Mar 17;10(6):1950-1959. doi: 10.1016/j.ekir.2025.03.019. eCollection 2025 Jun.
6
Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes.
Kidney Int Rep. 2025 Mar 24;10(6):2058-2061. doi: 10.1016/j.ekir.2025.03.028. eCollection 2025 Jun.
7
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial.
Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03750-3.
8
Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy.
Int J Rheum Dis. 2025 Jun;28(6):e70292. doi: 10.1111/1756-185X.70292.
9
Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge.
Diseases. 2025 May 15;13(5):153. doi: 10.3390/diseases13050153.
10
Treatment burden in glomerular diseases: advances and challenges in immunosuppressive therapy.
Front Nephrol. 2025 May 1;5:1545373. doi: 10.3389/fneph.2025.1545373. eCollection 2025.
本文引用的文献
1
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
Clin Kidney J. 2017 Oct;10(5):600-624. doi: 10.1093/ckj/sfx081. Epub 2017 May 8.
2
Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential.
Clin Kidney J. 2017 Aug;10(4):490-493. doi: 10.1093/ckj/sfx030. Epub 2017 May 8.
3
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
Kidney Int. 2017 Nov;92(5):1261-1271. doi: 10.1016/j.kint.2017.04.028. Epub 2017 Jul 24.
4
Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1237-1247. doi: 10.2215/CJN.00280117. Epub 2017 Jun 8.
5
Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
Kidney Int. 2017 Jun;91(6):1271-1274. doi: 10.1016/j.kint.2017.02.025.
6
Haemolytic uraemic syndrome.
Lancet. 2017 Aug 12;390(10095):681-696. doi: 10.1016/S0140-6736(17)30062-4. Epub 2017 Feb 25.
7
Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.
Kidney Int. 2017 Jun;91(6):1420-1425. doi: 10.1016/j.kint.2016.12.009. Epub 2017 Feb 7.
8
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab.
Ann Hematol. 2017 Apr;96(4):589-596. doi: 10.1007/s00277-017-2924-y. Epub 2017 Jan 26.
9
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.
10
Thrombotic Microangiopathy in Inverted Formin 2Mediated Renal Disease.
J Am Soc Nephrol. 2017 Apr;28(4):1084-1091. doi: 10.1681/ASN.2015101189. Epub 2016 Dec 14.
Zotero 插件